H&B Partners with Phlo: Navigating GLP-1 Impact on UK Weight Management Market
Holland & Barrett's collaboration with Phlo, a GLP-1 provider, broadens its weight management offering but presents complex regulatory and commercial dynamics for supplement brands in the UK.
AI-assisted coverage: produced by SF News' automated newsroom from the cited sources and checked by automated attribution gates. Editorial responsibility: Lee Smith, Group CEO. How we work →
London, United Kingdom — 08 May 2026
Holland & Barrett (H&B) has announced a strategic partnership with Phlo, a provider of GLP-1 weight management drugs, including Wegovy and Mounjaro. This move sees H&B, a prominent UK health retailer, integrate signposting for clinically supervised weight management services into its stores and online platforms. The initiative aims to cater to the significant demand for weight management solutions, with H&B's data indicating 55% of UK adults desire better weight management.
The partnership positions H&B as a clinical support pathway facilitator, not a prescriber. While H&B will direct customers towards Phlo's services, actual prescription remains subject to clinical eligibility checks by Phlo. This distinction is critical for H&B to maintain its retail identity and avoid regulatory entanglement with pharmaceutical dispensing. The retailer will, however, continue to offer its existing nutrition and wellness ranges, emphasising their role in supporting overall health during any weight management journey.
A key consideration is the nutritional impact of GLP-1 drugs. Research suggests approximately one in ten GLP-1 users develop at least one new nutritional deficiency within six months. H&B intends to offer nutritional advice to these individuals, focusing on general support like protein and fibre, rather than directly associating supplements with mitigating specific drug side effects. This cautious approach is dictated by the UK's regulatory environment, where linking supplements to prescription drug symptom management is prohibited and considered a medical claim, which could attract enforcement action from the MHRA or FSA.
This partnership reflects a broader industry trend towards retailers evolving into 'holistic wellness ecosystems', moving beyond product sales to offer integrated support and advice. H&B's Wellness Platform Director, Leila Thabet, stated the retailer’s commitment to offering ‘end-to-end solutions’ for customers navigating various health challenges. H&B confirmed ongoing investment in its own-brand weight management lines, with new product launches scheduled throughout 2026 and beyond, indicating a dual strategy of clinical referral and in-house product development.
What this means for United Kingdom
UK supplement manufacturers and brand owners must reassess product positioning given the rise of GLP-1s and H&B's new strategy. Brands need to develop robust marketing that highlights general nutritional support without encroaching on medical claims, particularly concerning GLP-1 side effects, to ensure FSA and MHRA compliance. Manufacturers should anticipate potential shifts in ingredient demand, moving towards macronutrients and micronutrients that support general wellness, rather than niche weight loss actives. Furthermore, brand owners must innovate their offerings to remain competitive against pharmaceutical interventions and H&B's expanded service model, potentially by focusing on personalised nutrition or lifestyle support.
For more on UK formulation and manufacturing best practice, learn more at Supplement Factory.